Mark Butler will provide funding for interim access to a new treatment for high-risk Neuroblastoma
Lucy Jones, CEO at Neuroblastoma Australia, shared on LinkedIn:
“Delighted to share the news that Mark Butler has agreed to provide funding for interim access to a new treatment for high-risk Neuroblastoma called DFMO.
This will ensure every child needing it here in Australia can access it for free, avoiding the need to fundraise hundreds of thousands of dollars and travel overseas with immuno-compromised children.
This action represents a big step forward, recognising the need to be more agile and responsive in order to help children with rare cancers.
Thank you to Mark Butler for making this happen.
I also wanted to express my thanks to all the politicians who have helped raise awareness of this pressing issue, to all the families who spoke out and to the media for all their help and also to CT Group who have provided pro bono support over the last 3 months.”
Source: Lucy Jones/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023